Home > Research > Press > New partnerships to support Lancaster COVID-19 ...
View graph of relations

New partnerships to support Lancaster COVID-19 vaccine rollout

Press/Media: Newspaper Article

Description

A pioneering needleless COVID-19 vaccine developed at Lancaster University is growing closer to reality after partnerships were signed with companies in South America and Asia to produce vital doses of the new vaccine for developing countries and remote regions. 

The University has joined forces with British life sciences company ViraCorp to further develop and commercialise the dual antigen-carrying intranasal vaccine through its subsidiary ViraVac. It is hoped the vaccine will have a major impact in protecting communities with dangerously low vaccination levels. 

The vaccine, which is the brainchild of renowned Lancaster University molecular virologist Dr Muhammad Munir, is currently going through a rigorous testing phase - but preparations are being put in place to begin mass production as soon as it is given the green light.

The new partnerships with Peruvian pharmaceutical firm FARVET SAC and Bangladesh’s Incepta Vaccine Ltd will help ensure production capacity is in place at the appropriate time.

Dr Munir said: “These partnerships with FARVET and Incepta are critical milestones in further developing our next generation COVID-19 vaccine, which offers protections and blocks transmission independent of the nature of SARS-COV-2 variants.

Period18/02/2022

A pioneering needleless COVID-19 vaccine developed at Lancaster University is growing closer to reality after partnerships were signed with companies in South America and Asia to produce vital doses of the new vaccine for developing countries and remote regions. 

The University has joined forces with British life sciences company ViraCorp to further develop and commercialise the dual antigen-carrying intranasal vaccine through its subsidiary ViraVac. It is hoped the vaccine will have a major impact in protecting communities with dangerously low vaccination levels. 

The vaccine, which is the brainchild of renowned Lancaster University molecular virologist Dr Muhammad Munir, is currently going through a rigorous testing phase - but preparations are being put in place to begin mass production as soon as it is given the green light.

The new partnerships with Peruvian pharmaceutical firm FARVET SAC and Bangladesh’s Incepta Vaccine Ltd will help ensure production capacity is in place at the appropriate time.

Dr Munir said: “These partnerships with FARVET and Incepta are critical milestones in further developing our next generation COVID-19 vaccine, which offers protections and blocks transmission independent of the nature of SARS-COV-2 variants.

References

TitleNew partnerships to support Lancaster COVID-19 vaccine rollout
Country/TerritoryUnited Kingdom
Date18/02/22
DescriptionA pioneering needleless COVID-19 vaccine developed at Lancaster University is growing closer to reality after partnerships were signed with companies in South America and Asia to produce vital doses of the new vaccine for developing countries and remote regions.

The University has joined forces with British life sciences company ViraCorp to further develop and commercialise the dual antigen-carrying intranasal vaccine through its subsidiary ViraVac. It is hoped the vaccine will have a major impact in protecting communities with dangerously low vaccination levels.

The vaccine, which is the brainchild of renowned Lancaster University molecular virologist Dr Muhammad Munir, is currently going through a rigorous testing phase - but preparations are being put in place to begin mass production as soon as it is given the green light.

The new partnerships with Peruvian pharmaceutical firm FARVET SAC and Bangladesh’s Incepta Vaccine Ltd will help ensure production capacity is in place at the appropriate time.

Dr Munir said: “These partnerships with FARVET and Incepta are critical milestones in further developing our next generation COVID-19 vaccine, which offers protections and blocks transmission independent of the nature of SARS-COV-2 variants.
PersonsMuhammad Munir